Growing Intellectual Property Portfolio

On January 13, 2023, NurExone received a notice of allowance from the United States Patent and Trademark Office (USPTO) for our U.S. Patent Application NO. 17/042,441. This patent application covers and protects our Exo-PTEN technology, drug composition, and methods for non-invasive intranasal administration of exosome-based treatment.

Our IP Portfolio consists of:

  • Intranasal ExoPTEN – received allowance
  • 2 PCTs – on Production and Composition of Matter of our exosomes
  • 4 provisional patents on loading technique and siRNA target sequences

Set layout popup